Gritstone fails to convince
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
ASCO-GI – Leap falters again
Randomised data will be needed to answer lingering questions about DKN-01.
ASCO-GI – confirmation for Bristol’s combo, but is there more?
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
Merck KGaA takes a punt on Inspirna’s novel approach
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.
Interview – Gritstone hopes to inject some interest
As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
